Quick Answer
Monopar Therapeutics reported Net Income of -$13.72 million for fiscal year 2025.
Monopar Therapeutics Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$13.72M | +12.0% |
| 2024 | -$15.59M | -85.5% |
| 2023 | -$8.40M | +20.1% |
| 2022 | -$10.52M | -15.5% |
| 2021 | -$9.10M | -44.4% |
| 2020 | -$6.30M | -49.2% |
| 2019 | -$4.22M | -30.9% |
| 2018 | -$3.23M | +80.5% |
| 2017 | -$16.55M | -1296.3% |
| 2016 | -$1.19M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$3.44M | -163.6% | -40.1% |
| June 30, 2025 | -$2.45M | -43.0% | +6.5% |
| March 31, 2025 | -$2.62M | -59.9% | -101.3% |
| September 30, 2024 | -$1.30M | +33.2% | +24.0% |
| June 30, 2024 | -$1.72M | +22.0% | -4.5% |
| March 31, 2024 | -$1.64M | +32.6% | +16.0% |
| September 30, 2023 | -$1.95M | +18.6% | +11.2% |
| June 30, 2023 | -$2.20M | +20.4% | +9.6% |
- Monopar Therapeutics showed an increase of +12.0% in Net Income compared to the prior fiscal year.
- Over the 2016–2025 period, Monopar Therapeutics’s net income has declined by 1057.0% (from -$1.19 million to -$13.72 million).
- The most recent figure is from Monopar Therapeutics’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: